Stakeholder Opinions: Ovarian Cancer - Approaching The Era Of Molecular Targeted Therapy

Introduction

Despite advances in the management of the disease, outcomes remain poor for patients with advanced epithelial ovarian cancer. The high level of unmet need, coupled with the large size of the patient population, is driving extensive R&D interest in this indication. The anticipated incorporation of molecular targeted therapies into treatment is expected to improve patient outcomes in the future.

Scope

*Ovarian cancer overview, including disease definition, epidemiology, discussion of unmet needs, and market potential

*Current treatment options for ovarian cancer and ongoing controversies

*Examination of the late-phase ovarian cancer pipeline, including drug profiles of late-stage agents

*Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU

Highlights

Ovarian cancer is the leading cause of death from gynecological malignancies in the Western world. This is because the majority of epithelial ovarian cancer patients present with advanced disease at diagnosis, where treatment has a palliative rather than curative intent.

While first-line platinum-based chemotherapy can result in high response rates of over 70-80%, the majority of patients will advanced epithelial ovarian cancer will eventually relapse with incurable disease. As such, there is a need for novel first-line therapies to improve survival rates.

R&D interest in ovarian cancer is high. There are currently 85 drugs in the pipeline, which is dominated by molecular targeted therapies (42%) and cytotoxic therapies (33%). Competition for the approval of the first molecular targeted therapy in ovarian cancer is fierce.

Reasons to Purchase

*Estimate the number of treatable patients and identify unmet needs for future drug development opportunities

*Understand the current treatment of the disease, as well as opportunities and threats in the ovarian cancer market

*Analyze the current ovarian cancer pipeline and the potential of late-stage drugs

Table of Contents :

Overview 1

Catalyst 1

Summary 1

About Datamonitor healthcare 2

About the Oncology pharmaceutical analysis team 2

Executive Summary 3

Scope of the analysis 3

Datamonitor insight into the ovarian cancer market 3

Related reports 4

Upcoming reports 4

TABLE OF CONTENTS 5

Patient Potential 6

Key findings 6

Definition 6

Epithelial tumors 7

The vast majority of ovarian cancers are epithelial in origin 7

The majority of epithelial ovarian cancers are sporadic in nature 8

Germ cell tumors 8

Sex cord-stromal tumors 8

A successful screening test for ovarian cancer has not been developed 8

Ovarian cancer is a surgically staged malignancy 9

Epidemiology 12

The incidence of ovarian cancer in the seven major markets is forecast to reach nearly 63,000 cases by 2019 12

The highest ovarian cancer rates prevail in Northern European countries 14

Current treatment options 15

Most early-stage patients are treated with surgery and chemotherapy 15

Surgery has a central role in the management of advanced disease 16

First-line platinum-based chemotherapy is the standard of care for advanced disease 17

The use of intraperitoneal chemotherapy remains controversial 20

Maintenance therapy has not been shown to improve overall survival 21

The treatment of recurrent disease is rarely curative and depends on patients' platinum sensitivity 22

Platinum-based combination chemotherapy is recommended for platinum-sensitive recurrent disease 23

A number of single agents can be used in the treatment of platinum-resistant recurrent disease 25

Unmet need 25

More effective agents are required for the treatment of advanced disease 25

An effective screening test could significantly improve patient survival 26

R&D efforts should be directed towards molecular targeted therapies 26

Less invasive surgical approaches should be explored for early-stage patients 27

Market potential 28

Key findings 28

Current market overview 28

Opportunities and threats 29

Opportunities 29

Significant unmet need remains in the treatment of advanced disease 29

There is increased interest in the development of molecular targeted therapies 30

There is a large patient base in ovarian cancer, and a high commercial attractiveness 30

Threats 30

For more information please visit :

http://www.aarkstore.com/reports/Stakeholder-Opinions-Ovarian-Cancer-Approaching-the-era-of-molecular-targeted-therapy-52743.html

by: Aarkstore Enterprise

POST COMMENT

Rosacea Natural Treatment That Works Getting to Know the ActiveFX Laser Treatment How Alcohol Treatment Center Steps in to Remove Alcoholism Rheumatoid Arthritis - Effects and Treatment Stop early ejaculation making use of natural treatment Is it feasible Botox Treatment Beverly Hills- Botox as Treatment of Wrinkles and Migraines What Are The Pros And Cons Of Teeth Whitening Treatment Diagnosis and Treatment at an Alcohol Treatment Center Life Extension Treatment and Chickens The 9 Most Common Areas for Liposuction Treatment Incontinence in Men: Many Different Treatment Options Six Easy Ways to Prevent Cancer Breast Cancer Survivors have Implant Preferences